Novo Nordisk recently introduced Wegovy subscriptions. Despite strong market rivalry, particularly from Eli Lilly's weight-loss pill, Wegovy received clearance from the UK drug price watchdog for heart disease treatment, expanding access by 1.2 million people. However, the company experienced a market drop after its obesity drug failed to beat Zepbound, contributing to a 16% plunge. A trial also showed their weight-loss drug inferior to an Eli Lilly rival. Yet, Wegovy outperformed Eli Lilly's counterpart in different clinical trial data and the stock has seen a growth spurt since a mention by Jim Cramer. The stock is currently trading down near its 5-year low, with shares down 43% over the year due to generic rivals leading to a 48% reduction in prices. The company has recently received regulatory approval of a new drug while also announcing a share repurchase program. It also warned of potential sales hits for the year and received a downgrade from Goldman Sachs. The stock hit its 52-week low, however, there are indications that it is undervalued. Lastly, the company also announced a $2.1 billion partnership with Vivtex for Oral Drug-Delivery Technologies.
Novo Nordisk Stocks News Analytics from Mon, 27 Oct 2025 07:00:00 GMT to Sat, 04 Apr 2026 18:32:00 GMT -
Rating -5
- Innovation -2
- Information 7
- Rumor -4
